Immunologic monitoring of cancer vaccine trials using the ELISPOT assay.

@article{Butterfield2014ImmunologicMO,
  title={Immunologic monitoring of cancer vaccine trials using the ELISPOT assay.},
  author={Lisa H Butterfield and Mary Jo Buffo},
  journal={Methods in molecular biology},
  year={2014},
  volume={1102},
  pages={71-82}
}
Cancer vaccines are designed to activate an immune response to tumor-specific or tumor-associated antigens expressed by the tumor. Cancer vaccines take many forms, including synthetic peptides, tumor cells and lysates, cell lines, and autologous antigen presenting cells like dendritic cells. The target antigens may be known, or "defined" in the vaccine, or unknown. In melanoma, more so than in other cancers, a large number of immunogenic "shared" antigens (tumor-specific or tumor-associated… CONTINUE READING